MoonLake Immunotherapeutics (MLTX) Other Non Operating Income (2021 - 2026)

MoonLake Immunotherapeutics' Other Non Operating Income history runs 6 years deep, the most recent figure standing at -$359000.0 for Q1 2026.

• On a quarterly basis, Other Non Operating Income fell 105.06% year-over-year to -$359000.0 in Q1 2026; TTM through Mar 2026 was $7.0 million, a 31.37% decrease from a year earlier, with the FY2025 full-year figure at $641000.0, down 97.1% from the prior year.
• Other Non Operating Income fell to -$359000.0 in Q1 2026 per MLTX's latest filing, from $525000.0 in the prior quarter.
• Across five years, Other Non Operating Income topped out at $7.2 million in Q4 2023 and bottomed at -$359000.0 in Q1 2026.
• The 5-year median for Other Non Operating Income is $39157.0 (2023), against an average of $1.4 million.
• Across the five-year window, Other Non Operating Income surged 10259.7% in 2022 and slumped 396.24% in 2024, its largest moves.
• Year by year, Other Non Operating Income stood at -$186990.0 in 2022, then jumped by 3942.69% to $7.2 million in 2023, then plunged by 55.1% to $3.2 million in 2024, then plunged by 83.73% to $525000.0 in 2025, then slumped by 168.38% to -$359000.0 in 2026.
• Per Business Quant, the three latest MLTX Other Non Operating Income figures stand at -$359000.0 (Q1 2026), $525000.0 (Q4 2025), and $8000.0 (Q3 2025).